Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells

References

• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492-507; PMID:18669428; http://dx.doi.org/10.1056/NEJMra0708126
   PubMed Web of Science ®Google Scholar
• DeAngelis LM. Brain tumors. N Engl J Med 2001; 344:114-23; PMID:11150363
   PubMed Web of Science ®Google Scholar
• Pollack IF. Brain tumors in children. N Engl J Med 1994; 331:1500-7; PMID:7969301
   PubMed Web of Science ®Google Scholar
• Ziegler DS, Kung AL, Kieran MW. Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 2008; 26:493-500; PMID:18202424; http://dx.doi.org/10.1200/JCO.2007.13.9717
   PubMed Web of Science ®Google Scholar
• Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007; 6:1909-19; PMID:17620423; http://dx.doi.org/10.1158/1535-7163.MCT-07-0047
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-24; PMID:16282176; http://dx.doi.org/10.1056/NEJMoa051918
   PubMed Web of Science ®Google Scholar
• Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996; 56:5079-86; PMID:8895767
   PubMed Web of Science ®Google Scholar
• Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan Cet al,, Cavenee WK Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21:2683-710; PMID:17974913; http://dx.doi.org/10.1101/gad.1596707
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001; 12:745-60; PMID:11484948; http://dx.doi.org/10.1023/A:1011177318162
   PubMed Web of Science ®Google Scholar
• Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12:5064-73; PMID:16951222; http://dx.doi.org/10.1158/1078-0432.CCR-06-0913
   PubMed Web of Science ®Google Scholar
• Ge H, Gong X, Tang CK. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 2002; 98:357-61; PMID:11920586; http://dx.doi.org/10.1002/ijc.10224
   PubMed Web of Science ®Google Scholar
• Li B, Yuan M, Kim IA, Chang CM, Bernhard EJ, Shu HK. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 2004; 23:4594-602; PMID:15077177; http://dx.doi.org/10.1038/sj.onc.1207602
   PubMed Web of Science ®Google Scholar
• Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003; 63:2742-6; PMID:12782577
   PubMed Web of Science ®Google Scholar
• Lorimer IA, Lavictoire SJ. Activation of extracellular-regulated kinases by normal and mutant EGF receptors. Biochim Biophys Acta 2001; 1538:1-9; PMID:11341977; http://dx.doi.org/10.1016/S0167-4889(00)00129-4
   PubMed Web of Science ®Google Scholar
• Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HS. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 1996; 271:25639-45; PMID:8810340; http://dx.doi.org/10.1074/jbc.271.41.25639
   PubMed Web of Science ®Google Scholar
• de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Depinho RA, Bonni A. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 2008; 22:449-62; PMID:18258752; http://dx.doi.org/10.1101/gad.1606508
   PubMed Web of Science ®Google Scholar
• Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19:2474-88; PMID:10851046; http://dx.doi.org/10.1038/sj.onc.1203527
   PubMed Web of Science ®Google Scholar
• Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A 1998; 95:5724-9; PMID:9576951; http://dx.doi.org/10.1073/pnas.95.10.5724
   PubMed Web of Science ®Google Scholar
• Wu JL, Abe T, Inoue R, Fujiki M, Kobayashi H. IkappaBalphaM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells. Neurol Res 2004; 26:785-91; PMID:15494123; http://dx.doi.org/10.1179/016164104225014139
   PubMed Web of Science ®Google Scholar
• Thaker NG, Zhang F, McDonald PR, Shun TY, Lazo JS, Pollack IF. Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development. Neurosurg Focus 2010; 28:E4; PMID:20043719
   PubMedGoogle Scholar
• Thaker NG, Pollack IF. Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother 2009; 9:1815-36; PMID:19951140; http://dx.doi.org/10.1586/ern.09.116
   PubMed Web of Science ®Google Scholar
• Thaker NG, Zhang F, McDonald PR, Shun TY, Lewen MD, Pollack IF, Lazo JS. Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol 2009; 76:1246-55; PMID:19783622; http://dx.doi.org/10.1124/mol.109.058024
   PubMed Web of Science ®Google Scholar
• Thaker NG, McDonald PR, Zhang F, Kitchens CA, Shun TY, Pollack IF, Lazo JS. Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets. J Neurosci Methods 2010; 185:204-12; PMID:19782703; http://dx.doi.org/10.1016/j.jneumeth.2009.09.023
   PubMed Web of Science ®Google Scholar
• Kitchens CA, McDonald PR, Shun TY, Pollack IF, Lazo JS. Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens. J Pharmacol Exp Ther 2011; 339:851-8; PMID:21880871; http://dx.doi.org/10.1124/jpet.111.184879
   PubMed Web of Science ®Google Scholar
• Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN; et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008; 68:2321-8; PMID:18381439; http://dx.doi.org/10.1158/0008-5472.CAN-07-5031
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T; et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10:375-88; PMID:17097560; http://dx.doi.org/10.1016/j.ccr.2006.10.006
   PubMed Web of Science ®Google Scholar
• Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J; Warner RB, Ng SC, Fesik SW, Elmore SW, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67:1176-83; PMID:17283153; http://dx.doi.org/10.1158/0008-5472.CAN-06-2203
   PubMed Web of Science ®Google Scholar
• van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE; Willis SN, Scott CL, Day CL, Cory S, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10:389-99; PMID:17097561; http://dx.doi.org/10.1016/j.ccr.2006.08.027
   PubMed Web of Science ®Google Scholar
• Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maiga S; Avet-Loiseau H, Bataille R, Moreau P, Le Gouill S, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011; 118:3901-10; PMID:21835956; http://dx.doi.org/10.1182/blood-2010-11-317438
   PubMed Web of Science ®Google Scholar
• Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Mol Cancer Ther 2013; 12:326-38; PMID:23325792; http://dx.doi.org/10.1158/1535-7163.MCT-12-0901
   PubMed Web of Science ®Google Scholar
• Jane EP, Premkumar DR, Morales A, Foster KA, Pollack IF. Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells. J Pharmacol Exp Ther 2014; 350:22-35; PMID:24741074; http://dx.doi.org/10.1124/jpet.114.212910
   PubMed Web of Science ®Google Scholar
• Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR, Pollack IF. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. J Pharmacol Exp Ther 2012; 341:859-72; PMID:22393246; http://dx.doi.org/10.1124/jpet.112.191536
   PubMed Web of Science ®Google Scholar
• Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C; et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008; 27:6646-56; PMID:18663354; http://dx.doi.org/10.1038/onc.2008.259
   PubMed Web of Science ®Google Scholar
• Premkumar DR, Jane EP, Agostino NR, DiDomenico JD, Pollack IF. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol Carcinog 2013; 52:118-33; PMID:22086447; http://dx.doi.org/10.1002/mc.21835
   PubMed Web of Science ®Google Scholar
• Foster KA, Jane EP, Premkumar DR, Morales A, Pollack IF. Co-administration of ABT-737 and SAHA induces apoptosis, mediated by Noxa upregulation, Bax activation and mitochondrial dysfunction in PTEN-intact malignant human glioma cell lines. J Neurooncol 2014; PMID:25139025
   PubMed Web of Science ®Google Scholar
• Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, Seifert V, Kögel D. The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res 2010; 8:1002-16; PMID:20587533; http://dx.doi.org/10.1158/1541-7786.MCR-09-0562
   PubMed Web of Science ®Google Scholar
• Cristofanon S, Fulda S. ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis 2012; 3:e432; PMID:23190604
   PubMedGoogle Scholar
• Lo HW, Cao X, Zhu H, Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 2008; 14:6042-54; PMID:18829483; http://dx.doi.org/10.1158/1078-0432.CCR-07-4923
   PubMed Web of Science ®Google Scholar
• Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 2009; 27:4422-32; PMID:19667270; http://dx.doi.org/10.1200/JCO.2008.21.3264
   PubMed Web of Science ®Google Scholar
• Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007; 25:2184-90; PMID:17538163; http://dx.doi.org/10.1200/JCO.2006.07.6554
   PubMed Web of Science ®Google Scholar
• Tweardy D, Chang JC. Stat5: from breast development to cancer prognosis, prediction, and progression. J Clin Oncol 2011; 29:2443-4; PMID:21576641; http://dx.doi.org/10.1200/JCO.2010.34.2014
   PubMed Web of Science ®Google Scholar
• Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63:1270-9; PMID:12649187
   PubMed Web of Science ®Google Scholar
• Shi X, Franko B, Frantz C, Amin HM, Lai R. JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br J Haematol 2006; 135:26-32; PMID:16939498; http://dx.doi.org/10.1111/j.1365-2141.2006.06259.x
   PubMed Web of Science ®Google Scholar
• Jung SH, Lee YK, Lee HJ, Choi NR, Vo MC, Hoang MD; Lim MS, Nguyen-Pham TN, Kim HJ, et al. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro. Exp Hematol 2014; 42:274-81; PMID:24407159; http://dx.doi.org/10.1016/j.exphem.2013.12.008
   PubMed Web of Science ®Google Scholar
• Gheeya JS, Chen QR, Benjamin CD, Cheuk AT, Tsang P, Chung JY, et al. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol Ther 2009; 8:2386-95; PMID:19946221; http://dx.doi.org/10.4161/cbt.8.24.10184
   PubMed Web of Science ®Google Scholar
• Molavi O, Ma Z, Mahmud A, Alshamsan A, Samuel J, Lai R, Kwon GS, Lavasanifar A. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors. Int J Pharm 2008; 347:118-27; PMID:17681440; http://dx.doi.org/10.1016/j.ijpharm.2007.06.032
   PubMed Web of Science ®Google Scholar
• Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW; Chang YL, Hsu HS, Lan YT, Chen KH, et al. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. J Pharmacol Exp Ther 2012; 341:410-23; PMID:22328572; http://dx.doi.org/10.1124/jpet.111.188730
   PubMed Web of Science ®Google Scholar
• Premkumar DR, Jane EP, Agostino NR, Scialabba JL, Pollack IF. Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells. J Carcinog 2010; 9; PMID:20808823
   PubMedGoogle Scholar
• Su Y, Li G, Zhang X, Gu J, Zhang C, Tian Z, Zhang J. JSI-124 inhibits glioblastoma multiforme cell proliferation through G(2)/M cell cycle arrest and apoptosis augment. Cancer Biol Ther 2008; 7:1243-9; PMID:18487947; http://dx.doi.org/10.4161/cbt.7.8.6263
   PubMed Web of Science ®Google Scholar
• Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, Shih HC, Hung SC, Chen YC, Tseng LM, Chiou SH. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 2011; 117:2970-85; PMID:21225866; http://dx.doi.org/10.1002/cncr.25869
   PubMed Web of Science ®Google Scholar
• Lieblein JC, Ball S, Hutzen B, Sasser AK, Lin HJ, Huang TH, Hall BM, Lin J. STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer 2008; 8:302; PMID:18939993; http://dx.doi.org/10.1186/1471-2407-8-302
   PubMed Web of Science ®Google Scholar
• Brady MT, Miller A, Sait SN, Ford LA, Minderman H, Wang ES, Lee KP, Baumann H, Wetzler M. Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function. Leuk Res 2013; 37:822-8; PMID:23628554; http://dx.doi.org/10.1016/j.leukres.2013.04.002
   PubMed Web of Science ®Google Scholar
• Ishdorj G, Johnston JB, Gibson SB. Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B leukemic cells. BMC Cancer 2011; 11:268; PMID:21702955; http://dx.doi.org/10.1186/1471-2407-11-268
   PubMed Web of Science ®Google Scholar
• Ishdorj G, Johnston JB, Gibson SB. Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis. Mol Cancer Ther 2010; 9:3302-14; PMID:21159613; http://dx.doi.org/10.1158/1535-7163.MCT-10-0550
   PubMed Web of Science ®Google Scholar
• Chen CL, Hsieh FC, Lieblein JC, Brown J, Chan C, Wallace JA, Cheng G, Hall BM, Lin J. Stat3 activation in human endometrial and cervical cancers. Br J Cancer 2007; 96:591-9; PMID:17311011; http://dx.doi.org/10.1038/sj.bjc.6603597
   PubMed Web of Science ®Google Scholar
• Chumbalkar V, Latha K, Hwang Y, Maywald R, Hawley L, Sawaya R; Diao L, Baggerly K, Cavenee WK, Furnari FB, et al. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of DeltaEGFR. J Proteome Res 2011; 10:1343-52; PMID:21214269; http://dx.doi.org/10.1021/pr101075e
   PubMed Web of Science ®Google Scholar
• Latha K, Li M, Chumbalkar V, Gururaj A, Hwang Y, Dakeng S, et al. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. Int J Cancer 2013; 132:509-20; PMID:22729867; http://dx.doi.org/10.1002/ijc.27690
   PubMed Web of Science ®Google Scholar
• Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J; et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63:6962-70; PMID:14583498
   PubMed Web of Science ®Google Scholar
• Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991; 51:2164-72; PMID:2009534
   PubMed Web of Science ®Google Scholar
• Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60:1383-7; PMID:10728703
   PubMed Web of Science ®Google Scholar
• Wang Q, Hirohashi Y, Furuuchi K, Zhao H, Liu Q, Zhang H, Murali R, Berezov A, Du X, Li B; et al. The centrosome in normal and transformed cells. DNA Cell Biol 2004; 23:475-89; PMID:15307950; http://dx.doi.org/10.1089/1044549041562276
   PubMed Web of Science ®Google Scholar
• Beltrami E, Plescia J, Wilkinson JC, Duckett CS, Altieri DC. Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem 2004; 279:2077-84; PMID:14581472; http://dx.doi.org/10.1074/jbc.M309479200
   PubMed Web of Science ®Google Scholar
• Kimura M, Yoshioka T, Saio M, Banno Y, Nagaoka H, Okano Y. Mitotic catastrophe and cell death induced by depletion of centrosomal proteins. Cell Death Dis 2013; 4:e603; PMID:23598415; http://dx.doi.org/10.1038/cddis.2013.108
   PubMed Web of Science ®Google Scholar
• Nabzdyk CS, Lancero H, Nguyen KP, Salek S, Conte MS. RNA interference-mediated survivin gene knockdown induces growth arrest and reduced migration of vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2011; 301:H1841-9; PMID:21856925; http://dx.doi.org/10.1152/ajpheart.00089.2011
   PubMedGoogle Scholar
• Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, Ecsedy JA. MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007; 27:4513-25; PMID:17438137; http://dx.doi.org/10.1128/MCB.02364-06
   PubMed Web of Science ®Google Scholar
• Li J, Anderson MG, Tucker LA, Shen Y, Glaser KB, Shah OJ. Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2. Cell Death Differ 2009; 16:498-511; PMID:19079141; http://dx.doi.org/10.1038/cdd.2008.174
   PubMed Web of Science ®Google Scholar
• Lee PY, Chen CL, Lin ZZ, Cheng AL, Chen EI, Whang-Peng J, Huang CY. The Aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme. Oncology 2013; 84:326-35; PMID:23636005; http://dx.doi.org/10.1159/000347021
   PubMed Web of Science ®Google Scholar
• Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 2003; 22:2934-47; PMID:12805209; http://dx.doi.org/10.1093/emboj/cdg307
   PubMed Web of Science ®Google Scholar
• Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 2013; 24:438-49; PMID:24135280; http://dx.doi.org/10.1016/j.ccr.2013.09.004
   PubMed Web of Science ®Google Scholar
• Wang YN, Yamaguchi H, Hsu JM, Hung MC. Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene 2010; 29:3997-4006; PMID:20473332; http://dx.doi.org/10.1038/onc.2010.157
   PubMed Web of Science ®Google Scholar
• Hochegger H, Hegarat N, Pereira-Leal JB. Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle. Open Biol 2013; 3:120185; PMID:23516109; http://dx.doi.org/10.1098/rsob.120185
   PubMed Web of Science ®Google Scholar
• Zhang XH, Rao M, Loprieato JA, Hong JA, Zhao M, Chen GZ, Humphries AE, Nguyen DM, Trepel JB, Yu X, Schrump DS. Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther 2008; 7:1388-97; PMID:18708766; http://dx.doi.org/10.4161/cbt.7.9.6415
   PubMed Web of Science ®Google Scholar
• Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007; 8:798-812; PMID:17848966; http://dx.doi.org/10.1038/nrm2257
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006; 12:6869-75; PMID:17145803; http://dx.doi.org/10.1158/1078-0432.CCR-06-1405
   PubMed Web of Science ®Google Scholar
• Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 2005; 11:3155-62; PMID:15867207; http://dx.doi.org/10.1158/1078-0432.CCR-04-2223
   PubMed Web of Science ®Google Scholar
• Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997; 272:2927-35; PMID:9006938; http://dx.doi.org/10.1074/jbc.272.5.2927
   PubMed Web of Science ®Google Scholar
• Furnari FB, Lin H, Huang HS, Cavenee WK. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A 1997; 94:12479-84; PMID:9356475; http://dx.doi.org/10.1073/pnas.94.23.12479
   PubMed Web of Science ®Google Scholar
• Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, von Deimling A, Dichgans J. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer 1998; 79:640-4; PMID:9842975; http://dx.doi.org/10.1002/(SICI)1097-0215(19981218)79:6%3c640::AID-IJC15%3e3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Jane EP, Premkumar DR, Pollack IF. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol Cancer Ther 2011; 10:198-208; PMID:21220502; http://dx.doi.org/10.1158/1535-7163.MCT-10-0725
   PubMed Web of Science ®Google Scholar
• Riss TL MR. Comparison of MTT, XTT and a novel tetrazolium compound MTS for in vitro proliferation and chemosensitivity assays. Mol Biol Cell 1992; 3:184
   Google Scholar